Search hospitals > Pennsylvania > Philadelphia
University of Pennsylvania
Claim this profilePhiladelphia, Pennsylvania 19104
Global Leader in Human Immunodeficiency Virus Infection
Global Leader in Heart Failure
Conducts research for Antiretroviral Therapy
Conducts research for Hypertension
Conducts research for Breast Cancer
1932 reported clinical trials
268 medical researchers
Summary
University of Pennsylvania is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Human Immunodeficiency Virus Infection, Heart Failure, Antiretroviral Therapy, Hypertension, Breast Cancer and other specialties. University of Pennsylvania is involved with conducting 1,932 clinical trials across 2,223 conditions. There are 268 research doctors associated with this hospital, such as Nimesh Desai, MD, Arati Desai, MD, Angela DeMichele, MD, and Wilson Szeto, MD.Area of expertise
1Human Immunodeficiency Virus Infection
Global Leader2Heart Failure
Global LeaderStage II
Stage IV
Stage III
Top PIs
Nimesh Desai, MDUniversity of Pennsylvania4 years of reported clinical research
Studies Ascending Aortic Aneurysm
Studies Aortic Dissection
13 reported clinical trials
17 drugs studied
Arati Desai, MDAbrams Cancer Center of the University of Pennsylvania6 years of reported clinical research
Studies Glioblastoma
Studies Brain Tumor
11 reported clinical trials
25 drugs studied
Angela DeMichele, MDAbramson Cancer Center of the University of Pennsylvania8 years of reported clinical research
Expert in Breast Cancer
Studies Breast cancer
11 reported clinical trials
20 drugs studied
Wilson Szeto, MDThe Hospital of the University of Pennsylvania6 years of reported clinical research
Studies Thoracoabdominal Aortic Aneurysms
Studies Retinal Aneurysm
10 reported clinical trials
13 drugs studied
Clinical Trials running at University of Pennsylvania
Heart Failure
Colorectal Cancer
Lymphoma
Age-Related Macular Degeneration
Pancreatic Cancer
Atrial Fibrillation
Uterine Tumors
Thyroid Fibrosis
Non-Hodgkin's Lymphoma
Hepatocellular Carcinoma
Catheter Ablation + HF Therapies
for Heart Failure and Atrial Fibrillation
Heart failure (HF) with preserved left ventricular function (pEF) is difficult clinical syndrome to treat effectively with few evidence based therapies. Atrial fibrillation (AF) is now an important co-morbidity being observed in 43% of patients with HFpEF. Rhythm control has not been studied in this population. Catheter ablation and antiarrhythmic drugs are rhythm control therapies that have been used for treatment of AF without HF or HF with reduced systolic function but have not been widely applied in HFpEF. No controlled comparative evaluation has been performed in HFpEF. The introduction of wireless pulmonary artery hemodynamic monitoring has permitted optimization of HF therapy in patients with chronic HF with reduced and preserved EF. Reduction in HF hospitalizations has been observed in post hoc analyses of HFpEF patients but has not been systematically applied in AF patients with HFpEF. In this study, we propose to study both rhythm control and optimized HF therapeutic approaches in an AF with HFpEF study population in a pilot study using a sequential two phase randomized controlled clinical trial design.
Recruiting3 awards Phase 413 criteria
Sitagliptin
for Type 2 Diabetes with Genetic Mutation
This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.
Recruiting2 awards Phase 43 criteria
Ziltivekimab
for Heart Failure and Inflammation
The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.
Recruiting1 award Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at University of Pennsylvania?
University of Pennsylvania is a medical facility located in Philadelphia, Pennsylvania. This center is recognized for care of Human Immunodeficiency Virus Infection, Heart Failure, Antiretroviral Therapy, Hypertension, Breast Cancer and other specialties. University of Pennsylvania is involved with conducting 1,932 clinical trials across 2,223 conditions. There are 268 research doctors associated with this hospital, such as Nimesh Desai, MD, Arati Desai, MD, Angela DeMichele, MD, and Wilson Szeto, MD.
Where is University of Pennsylvania located?
**Hospital of the University of Pennsylvania Directions:**
- To reach the Hospital of the University of Pennsylvania, take I-676 West to I-76 East (Schuylkill Expressway) and exit at 346-A (South Street). Turn right onto South Street to enter the campus.
**Pennsylvania Hospital Location:**
- Pennsylvania Hospital is situated at 800 Spruce Street, with the main entrance located on 8th Street.
Who should I call to ask about financial aid or insurance network?
For financial assistance at the University of Pennsylvania Hospital:
- Contact: 800-406-1177 or request online via MyLGHealth.
- Insurance inquiries: Contact Penn Medicine's insurance and billing department at 800-406-1177.
- Availability: Monday to Friday, 8:00 am to 6:00 pm EST; Saturday, 9:00 am to 1:00 pm EST.
What insurance does University of Pennsylvania accept?
The University of Pennsylvania Hospital accepts a wide range of insurance plans, including but not limited to Medicare Advantage, Pennsylvania Medical Assistance Managed Care (Medicaid), and Community HealthChoices (CHC). For Penn Cutaneous Pathology services, accepted insurances extend to Aetna, AmeriHealth, Keystone Health Plan East, and many others. Additionally, the Penn Student Insurance Plan (PSIP) through Aetna Student Health is available for most graduate and professional program students, meeting Penn's insurance requirements.
What awards or recognition has University of Pennsylvania received?
The University of Pennsylvania Hospital in Philadelphia is renowned for its clinical research studies, focusing on the prevention, diagnosis, and treatment of diseases. Its research laboratory specializes in imaging analytics, machine learning, pattern recognition, and computational imaging. This work is supported by the Pennsylvania Department of Health and NIH through multiple grants.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.